Biotech Startups

Caravel engineers proteins into scalable industrial "protein machines" for applications including critical minerals recovery, carbon capture, and industrial processes. The company develops a protein engineering platform aimed at reducing the time and cost of scaling proteins for industrial use.

5 investors

Cellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.

5 investors

Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies. The company serves biopharmaceutical manufacturers and cell therapy developers worldwide.

5 investors

Cellbricks Therapeutics is a preclinical biotech company developing implantable tissue grafts using proprietary bioprinting technology, biomaterials, and human cells for regenerative medicine applications. The company combines deep tech innovation to restore tissue function at clinical scale across multiple therapeutic programs.

5 investors

CellType uses AI agents and biological models to automate drug discovery, having identified a novel cancer treatment signal and partnering with major pharmaceutical companies.

5 investors

CellVoyant is an AI-first company that develops predictive analytics and optimization tools for cell-based therapeutic development, helping researchers accelerate process development and reduce costs through label-free imaging analysis and data-driven process optimization.

5 investors

Centenara Labs is a longevity-focused drug discovery company that translates research on the biology of aging into therapies intended to improve healthy aging and extend lifespan. It works with a global team drawn from medical and scientific institutions to develop longevity drugs and related technologies.

5 investors

CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches. It applies AI and structure-based drug discovery to design potent inhibitors targeting protein-ligand interactions at the KMT2A interface on menin.

5 investors

Checkpoint Surgical develops intraoperative nerve stimulation devices, biomaterial implants, and surgical instruments for peripheral nerve and tendon surgery. The company produces ACMShield, a dehydrated placental membrane allograft used as a protective barrier in surgical applications.

5 investors

ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.

5 investors

CircNova uses artificial intelligence to generate, analyze, and identify circular RNA structures for therapeutic development. The company focuses on non-coding RNA therapeutics targeting previously undruggable disease targets and major unmet clinical needs.

5 investors

Citruslabs is a clinical research organization that designs and runs consumer perception studies, clinical trials, and randomized controlled trials for health and wellness brands including supplements, skincare, pet health, biotech, and functional foods. The company translates study results into marketing-ready, regulator-reviewed product claims for consumer health brands that traditionally lack access to affordable clinical evidence.

5 investors

Clerio Vision is a development-stage medical device company developing LIRIC, a femtosecond laser technology that changes the refractive index of lens materials or corneal tissue without cutting or removing tissue. It applies this platform across four ophthalmic areas—multifocal contact lenses, myopia control lenses, post-implant intraocular lens adjustment, and incisionless laser vision correction—for patients with presbyopia, myopia, and other refractive errors.

5 investors

Clever Carnivore develops cultivated meat — beef, pork, and chicken grown from animal tissue samples in a food production facility — as an alternative to industrial farm-raised meat. The company targets the consumer market with cultivated meat products, including a bratwurst, focused on low-cost, scalable production.

5 investors

Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer. The company focuses on expanding its pipeline of clinical-stage candidates targeting the tumor microenvironment.

5 investors

Collate builds AI-native software to automate documentation workflows across drug development and commercialization for life sciences companies. The platform uses machine learning to reduce manual paperwork so research and commercial teams can focus on advancing their core work.

5 investors

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration. A University of Manchester spinout, it runs clinical and natural history studies in ophthalmology across the US and UK.

5 investors

Harvard University is an educational institution founded in 1636 that conducts research, offers undergraduate and graduate degree programs, and provides online learning to millions of learners globally. The university serves students, researchers, faculty, and a global community of alumni and online learners across multiple academic disciplines.

5 investors

Convexia provides AI-powered drug discovery and evaluation software that scans global sources for overlooked drug assets and runs deep in silico simulations across 50+ models to assess binding, toxicity, pharmacokinetics, and immunogenicity. The platform combines AI agents with expert human review to accelerate drug asset evaluation for biotech companies, pharma firms, and venture investors.

5 investors

COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function. The company is advancing a pipeline of disease-modifying therapies aimed at patients with a range of autoimmune conditions.

5 investors

Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid. Its lead investigational therapy is a selective URAT1 inhibitor designed to lower serum uric acid by targeting renal urate reabsorption pathways.

5 investors

Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.

5 investors

CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue. It advances a pipeline of Probody therapeutics through preclinical research and clinical trials in oncology.

5 investors

DD Pharmatech develops therapeutics for metabolic disorders, with a focus on oral and long-acting GLP-1 receptor agonist formulations. The company aims to build a global biotech business through innovative drug development technology.

5 investors